Search This Blog

 


▶ Fluvoxamine moderately to markedly increases the exposure

to aminophylline. Avoid.rStudy

▶ Fluvoxamine decreases the clearance of anaesthetics, local

(ropivacaine). Avoid prolonged use.oStudy

▶ Fluvoxamine is predicted to increase the exposure to

anagrelide.oTheoretical → Also see TABLE 4 p. 1375

▶ Antiarrhythmics (dronedarone) are predicted to increase the

exposure to dapoxetine. Adjust dapoxetine dose with moderate

inhibitors of CYP3A4, p. 821.oTheoretical

▶ Antiarrhythmics (dronedarone) are predicted to increase the

exposure to SSRIs (citalopram, escitalopram, fluoxetine,

fluvoxamine, paroxetine, sertraline).rTheoretical → Also see

TABLE 9 p. 1377

▶ Fluvoxamine is predicted to increase the exposure to

antiarrhythmics

o

(propafenone). Monitor and adjust dose.

Study

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to anticholinesterases, centrally acting (galantamine).

Monitor and adjust dose.oStudy

▶ Antiepileptics (fosphenytoin, phenytoin) decrease the

concentration of paroxetine.oStudy

▶ Sertraline potentially increases the risk of toxicity when given

with antiepileptics (fosphenytoin, phenytoin). Monitor

concentration and adjust dose.rAnecdotal

▶ SSRIs (fluoxetine, fluvoxamine) are predicted to increase the

concentration of antiepileptics (fosphenytoin, phenytoin).

Monitor and adjust dose.rAnecdotal

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the exposure to dapoxetine. Adjust

dapoxetine

o

dose with moderate inhibitors of CYP3A4, p. 821.

Theoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to moderately increase the exposure to dapoxetine.

Avoid potent inhibitors of CYP3A4 or adjust dapoxetine dose,

p. 821.rStudy

▶ Antifungals, azoles (voriconazole) are predicted to increase the

exposure to citalopram.rTheoretical → Also see TABLE 9

p. 1377

▶ Antihistamines, sedating (cyproheptadine) potentially decrease

the effects of SSRIs.oAnecdotal

▶ Apalutamide is predicted to decrease the exposure to

citalopram. Avoid or monitor.nStudy → Also see TABLE 9

p. 1377

▶ Aprepitant is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to moderately

increase the exposure to aripiprazole. Adjust aripiprazole dose,

p. 395.oStudy

▶ Fluvoxamine

Study

increases the exposure to asenapine.o ▶ Paroxetine

o

moderately increases the exposure to asenapine.

Study

▶ SSRIs (fluoxetine, paroxetine) are predicted to markedly

increase the exposure to

Study

atomoxetine. Adjust dose.r

1530 Sodium stibogluconate — SSRIs BNF 78

Interactions | Appendix 1

A1

▶ Fluvoxamine moderately increases the concentration of beta

blockers, non-selective (propranolol).oStudy

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to

o

beta blockers, selective (metoprolol, nebivolol).

Study

▶ Bupropion

o

is predicted to increase the exposure to dapoxetine.

Theoretical → Also see TABLE 13 p. 1378

▶ Fluvoxamine markedly decreases the clearance of caffeine

citrate. Monitor and adjust dose.rStudy

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to dapoxetine. Adjust dapoxetine dose

with moderate inhibitors of CYP3A4, p. 821.oTheoretical

▶ SSRIs (fluoxetine, fluvoxamine) are predicted to increase the

exposure to

Theoretical →

cilostazol

Also see TABLE 4

. Adjust

p. 1375

cilostazol dose, p. 232.o ▶ Cinacalcet

o

is predicted to increase the exposure to dapoxetine.

Theoretical

▶ Fluvoxamine is predicted to increase the exposure to

cinacalcet. Adjust dose.oTheoretical

▶ SSRIs (fluoxetine, fluvoxamine) potentially increase the

exposure to clobazam. Adjust dose.oTheoretical

▶ SSRIs (fluoxetine, fluvoxamine) are predicted to decrease the

efficacy of clopidogrel. Avoid.rTheoretical → Also see

TABLE 4 p. 1375

▶ Fluvoxamine increases the concentration of clozapine. Monitor

side effects and adjust dose.rStudy

▶ Cobicistat is predicted to moderately increase the exposure to

dapoxetine. Avoid potent inhibitors of CYP3A4 or adjust

dapoxetine dose, p. 821.rStudy

▶ Crizotinib is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to slightly increase

the exposure to darifenacin.nStudy

▶ Fluvoxamine

o

moderately increases the exposure to diazepam.

Study

▶ Fluvoxamine is predicted to increase the exposure to dopamine

receptor agonists (ropinirole). Adjust dose.oStudy

▶ Fluvoxamine markedly increases the exposure to duloxetine.

Avoid.rStudy → Also see TABLE 18 p. 1379 → Also see TABLE 13

p. 1378 → Also see TABLE 4 p. 1375

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to eliglustat. Avoid or adjust dose—consult product

literature.rStudy

▶ Fluvoxamine is predicted to increase the exposure to

eltrombopag.oTheoretical

▶ Fluvoxamine is predicted to increase the exposure to erlotinib.

Monitor side effects and adjust dose.oTheoretical

▶ Fluvoxamine

r

increases the concentration of frovatriptan.

Study → Also see TABLE 13 p. 1378

▶ Grapefruit juice moderately increases the exposure to

sertraline. Avoid.oStudy

▶ H2 receptor antagonists (cimetidine) slightly increase the

exposure to

o SSRIs (citalopram, escitalopram). Adjust dose.

Study

▶ H2 receptor antagonists (cimetidine) slightly increase the

exposure to SSRIs (paroxetine, sertraline).oStudy

▶ Fluoxetine increases the concentration of haloperidol. Adjust

dose.oAnecdotal

▶ Fluvoxamine increases the concentration of haloperidol.

Adjust dose.oStudy

▶ HIV-protease inhibitors are predicted to moderately increase

the exposure to dapoxetine. Avoid potent inhibitors of

CYP3A4 or adjust dapoxetine dose, p. 821.rStudy

▶ Idelalisib is predicted to moderately increase the exposure to

dapoxetine. Avoid potent inhibitors of CYP3A4 or adjust

dapoxetine dose, p. 821.rStudy

▶ Imatinib is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ Fluoxetine is predicted to increase the exposure to lomitapide.

Separate administration by 12 hours.qTheoretical

▶ Fluvoxamine is predicted to increase the exposure to

lomitapide

Theoretical

. Separate administration by 12 hours.o

▶ Fluvoxamine is predicted to increase the exposure to loxapine.

Avoid.qTheoretical

▶ Macrolides (clarithromycin) are predicted to moderately

increase the exposure to dapoxetine. Avoid potent inhibitors

of CYP3A4 or adjust dapoxetine dose, p. 821.rStudy

▶ Macrolides (erythromycin) are predicted to increase the

exposure to dapoxetine. Adjust dapoxetine dose with moderate

inhibitors of CYP3A4, p. 821.oTheoretical

▶ Fluvoxamine very markedly increases the exposure to

melatonin. Avoid.rStudy

▶ SSRIs (fluoxetine, fluvoxamine, paroxetine) are predicted to

increase the exposure to mexiletine.oStudy

▶ Netupitant is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ SSRIs potentially increase the risk of prolonged

neuromuscular blockade when given with neuromuscular

blocking drugs, non-depolarising

Theoretical

(mivacurium).q ▶ Nilotinib is predicted to increase the exposure to dapoxetine.

Adjust dapoxetine dose with moderate inhibitors of CYP3A4,

p. 821.oTheoretical

▶ Fluvoxamine moderately increases the exposure to olanzapine.

Adjust dose.rAnecdotal

▶ SSRIs (fluoxetine, paroxetine) are predicted to decrease the

efficacy of opioids (codeine).oTheoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to decrease the

efficacy of opioids (tramadol).rStudy → Also see TABLE 13

p. 1378

▶ Fluvoxamine is predicted to increase the exposure to

pentoxifylline.oTheoretical

▶ Fluvoxamine is predicted to moderately increase the exposure

to pirfenidone. Avoid.oStudy

▶ SSRIs (fluoxetine, paroxetine) are predicted to moderately

increase the exposure to pitolisant. Use with caution and

adjust dose.oStudy

▶ Fluvoxamine moderately increases the exposure to

pomalidomide. Adjust pomalidomide dose, p. 961.oStudy

▶ Paroxetine slightly increases the exposure to procyclidine.

Monitor and adjust dose.oStudy

▶ Proton pump inhibitors (esomeprazole) are predicted to slightly

to moderately increase the exposure to SSRIs (citalopram,

escitalopram). Monitor and adjust dose.rTheoretical

▶ Proton pump inhibitors (omeprazole) slightly to moderately

increase the exposure to SSRIs (citalopram, escitalopram).

Monitor and adjust dose.rStudy

▶ Fluvoxamine

o

is predicted to increase the exposure to riluzole.

Theoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to risperidone. Adjust dose.oStudy

▶ Fluvoxamine is predicted to increase the exposure to

roflumilast.oStudy

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to SSRIs (dapoxetine).oTheoretical → Also see

TABLE 18 p. 1379 → Also see TABLE 13 p. 1378 → Also see TABLE 4

p. 1375

▶ SSRIs potentially increase the risk of prolonged

neuromuscular blockade when given with

q

suxamethonium.

Theoretical

▶ SSRIs (fluoxetine, paroxetine) are predicted to decrease the

efficacy of tamoxifen. Avoid.rStudy

▶ Terbinafine is predicted to increase the exposure to fluoxetine.

Adjust dose.oTheoretical

▶ Terbinafine

o

moderately increases the exposure to paroxetine.

Study

▶ Terbinafine is predicted to increase the exposure to SSRIs

(citalopram, dapoxetine, escitalopram, fluvoxamine, sertraline)

o .

Theoretical

▶ Fluvoxamine moderately to markedly increases the exposure

to theophylline. Avoid.rStudy

▶ Fluvoxamine very markedly increases the exposure to

tizanidine. Avoid.rStudy

▶ SSRIs (fluoxetine, fluvoxamine) given with a moderate CYP3A4

inhibitor are predicted to increase the exposure to tofacitinib.

Adjust tofacitinib dose, p. 1105.oStudy

BNF 78 SSRIs — SSRIs 1531

Interactions | Appendix 1

A1

SSRIs (continued)

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to tricyclic antidepressants. Monitor for toxicity and

adjust dose.rStudy → Also see TABLE 18 p. 1379 → Also see

TABLE 13 p. 1378

▶ Fluvoxamine increases the exposure to tricyclic antidepressants

(amitriptyline, imipramine). Adjust dose.rStudy → Also see

TABLE 18 p. 1379 → Also see TABLE 13 p. 1378

▶ Fluvoxamine markedly increases the exposure to tricyclic

antidepressants (clomipramine). Adjust dose.rStudy → Also

see TABLE 18 p. 1379 → Also see TABLE 13 p. 1378

▶ SSRIs (fluoxetine, paroxetine) are predicted to increase the

exposure to

Study → Also see

vortioxetine

TABLE 13 p. 1378

. Monitor and adjust dose.

→ Also see TABLE 4 p. 1375

o ▶ Fluvoxamine is predicted to increase the exposure to

zolmitriptan

Theoretical →

. Adjust

Also see TABLE 13

zolmitriptan

p. 1378

dose, p. 482.r

St John’s Wort → see TABLE 13 p. 1378 (serotonin syndrome)

▶ St John’s Wort is predicted to decrease the exposure to

abemaciclib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

afatinib.oStudy

▶ St John’s Wort is predicted to slightly decrease the exposure to

aldosterone antagonists (eplerenone). Avoid.oStudy

▶ St John

Study

’s Wort decreases the exposure to aliskiren.o ▶ St John’s Wort moderately decreases the exposure to

alprazolam.oStudy

▶ St John’s Wort is predicted to decrease the concentration of

aminophylline.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

antiarrhythmics (dronedarone). Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

antiepileptics (brivaracetam).oTheoretical

▶ St John’s Wort is predicted to decrease the concentration of

antiepileptics

o

(carbamazepine). Monitor and adjust dose.

Theoretical

▶ St John’s Wort is predicted to decrease the concentration of

antiepileptics (fosphenytoin, phenobarbital, phenytoin,

primidone). Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

antiepileptics

Theoretical

(perampanel). Monitor and adjust dose.o ▶ St John’s Wort is predicted to decrease the exposure to

antiepileptics (tiagabine). Avoid.nTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

antifungals, azoles (isavuconazole). Avoid.rTheoretical

▶ St John’s Wort moderately decreases the exposure to

antifungals, azoles (voriconazole). Avoid.oStudy

▶ St John’s Wort is predicted to decrease the concentration of

antimalarials (piperaquine). Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

apixaban. Use with caution or avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

apremilast. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

aprepitant. Avoid.oTheoretical

▶ St John

o’s Wort is predicted to decrease the exposure to axitinib.

Theoretical

▶ St John’s Wort is predicted to decrease the exposure to

bedaquiline. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

bictegravir. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

bosentan. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

bosutinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

brigatinib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

cabozantinib.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to calcium

channel blockers (amlodipine, felodipine, lacidipine,

lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and

adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to calcium

channel blockers (diltiazem, verapamil).oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

cariprazine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ceritinib. Avoid.rTheoretical

▶ St John’s Wort decreases the concentration of ciclosporin.

Avoid.oStudy

▶ St John

o’s Wort is predicted to alter the effects of cilostazol.

Theoretical

▶ St John’s Wort is predicted to decrease the exposure to

cobicistat. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

cobimetinib. Avoid.rTheoretical

▶ St John’s Wort decreases the efficacy of combined hormonal

contraceptives. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rAnecdotal

▶ St John’s Wort decreases the anticoagulant effect of coumarins.

Avoid.rAnecdotal

▶ St John’s Wort is predicted to decrease the exposure to

crizotinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

dabigatran. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

darifenacin.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

dasabuvir. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

dasatinib.rStudy

▶ St John’s Wort is predicted to decrease the efficacy of

desogestrel. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rTheoretical

▶ St John

r’s Wort decreases the concentration of digoxin. Avoid.

Anecdotal

▶ St John’s Wort decreases the exposure to dolutegravir. Adjust

dose.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

doravirine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

edoxaban.oStudy

▶ St John’s Wort is predicted to decrease the concentration of

efavirenz. Avoid.rTheoretical

▶ St John’s Wort is predicted to moderately decrease the

exposure to elbasvir. Avoid.rStudy

▶ St John’s Wort is predicted to increase the exposure to

eliglustat. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the concentration of

elvitegravir. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

encorafenib.rTheoretical

▶ St John’s Wort is predicted to decrease the effects of

ergotamine.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

erlotinib.rTheoretical

▶ St John’s Wort is predicted to decrease the efficacy of

etonogestrel. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

etravirine. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the concentration of

everolimus. Avoid or adjust dose.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

exemestane.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

fesoterodine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

fingolimod. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

fosaprepitant. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

gefitinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

glecaprevir. Avoid.rStudy

▶ St John’s Wort is predicted to markedly decrease the exposure

to grazoprevir. Avoid.rStudy

1532 SSRIs — St John’s Wort BNF 78

Interactions | Appendix 1

A1

▶ St John’s Wort is predicted to decrease the concentration of

guanfacine. Adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to HIVprotease inhibitors. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the efficacy of hormone

replacement therapy.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ibrutinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

idelalisib. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

imatinib.oStudy

▶ St John’s Wort slightly decreases the exposure to irinotecan.

Avoid.rStudy

▶ St John

o’s Wort decreases the exposure to ivabradine. Avoid.

Study

▶ St John’s Wort is predicted to decrease the exposure to

ivacaftor.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ixazomib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

lapatinib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

ledipasvir. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the concentration of

letermovir.oTheoretical

▶ St John’s Wort is predicted to decrease the efficacy of

levonorgestrel. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

lurasidone. Monitor and adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

macitentan. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

maraviroc. Avoid.rTheoretical

▶ St John’s Wort moderately decreases the exposure to

midazolam. Monitor and adjust dose.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

midostaurin. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

naloxegol. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

netupitant.oTheoretical

▶ St John’s Wort is predicted to decrease the concentration of

nevirapine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

nilotinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

nintedanib.oStudy

▶ St John’s Wort is predicted to decrease the efficacy of

norethisterone. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rAnecdotal

▶ St John’s Wort is predicted to decrease the exposure to

olaparib. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ombitasvir. Avoid.rTheoretical

▶ St John’s Wort decreases the exposure to opioids (methadone).

Monitor and adjust dose.rStudy → Also see TABLE 13 p. 1378

▶ St John’s Wort moderately decreases the exposure to opioids

(oxycodone). Adjust dose.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

osimertinib. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ospemifene.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

palbociclib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

paliperidone.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

panobinostat. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

paritaprevir

Study

(with ritonavir and ombitasvir). Avoid.r

▶ St John’s Wort is predicted to decrease the exposure to

phosphodiesterase type-5 inhibitors.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

pibrentasvir. Avoid.rStudy

▶ St John’s Wort slightly decreases the exposure to pioglitazone.

nStudy

▶ St John’s Wort is predicted to decrease the exposure to

pitolisant. Monitor and adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

ponatinib. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

quetiapine.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

ranolazine. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

ribociclib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

rilpivirine. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

rolapitant. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

ruxolitinib. Monitor and adjust dose.oTheoretical

▶ St John’s Wort is predicted to decrease the concentration of

sirolimus. Monitor and adjust dose.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

sofosbuvir. Avoid.rStudy

▶ St John’s Wort slightly decreases the exposure to statins

(atorvastatin).nStudy

▶ St John’s Wort moderately decreases the exposure to statins

(simvastatin).oStudy

▶ St John’s Wort decreases the concentration of tacrolimus.

Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to taxanes

(cabazitaxel). Avoid.rStudy

▶ St John’s Wort is predicted to decrease the concentration of

temsirolimus. Avoid.rTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

tenofovir alafenamide. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

tezacaftor. Avoid.rTheoretical

▶ St John’s Wort potentially decreases the exposure to

theophylline.rAnecdotal

▶ St John’s Wort is predicted to decrease the exposure to

ticagrelor.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

tivozanib. Avoid.rStudy

▶ St John’s Wort is predicted to decrease the exposure to

tofacitinib.oStudy

▶ St John’s Wort is predicted to decrease the exposure to

tolvaptan. Avoid.oTheoretical

▶ St John’s Wort is predicted to decrease the exposure to

No comments:

Post a Comment

اكتب تعليق حول الموضوع

mcq general

 

Search This Blog